PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that preclinical data from several
investigational antibody-drug conjugate candidates in development, each in
separate studies, demonstrated enhanced anti-tumor activity in xenograft
models when compared to the anti-cancer antibodies alone. The use of
antibody- drug conjugate candidates is another new strategy to fight cancer
by targeting molecules implicated in disease (including B7-H4,
prostate-specific membrane antigen, mindin/RG1, CD70 and Ptk7) with
antibodies linked to cytotoxic agents that are designed to kill cancer
cells. Results from the preclinical studies were presented at the Annual
Meeting of the American Association for Cancer Research (AACR), being held
April 12-16, 2008 in San Diego.
"Our research and expertise in the antibody field continues to broaden
our pipeline with potentially important anti-cancer agents," said Howard H.
Pien, President and CEO of Medarex. "We are encouraged by the single-dose
efficacy observed in animal models from our antibody-drug conjugate
technology platform, and remain on track to prepare for our first
antibody-drug conjugate candidate IND filing this year."
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed herein relating to the preclinical data on multiple antibody-drug
conjugate candidates may constitute forward-looking statements that are
subject to certain risks and uncertainties that could cause actual results
to differ materially from any future results, performance or achievements
expressed or implied by such statements. Statements that are not historical
facts, including statements preceded by, followed by, or that include the
words "potential"; "may"; or similar statements are forward-looking
statements. Medarex disclaims, however, any intent or obligation to update
these forward- looking statements. Risks and uncertainties include risks
associated with product development, unforeseen safety issues resulting
from the administration of antibody products in humans, as well as risks
detailed from time to time in Medarex's public disclosure filings with the
U.S. Securities and Exchange Commission (SEC), including its Annual Report
on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly
reports on Form 10-Q. There can be no assurance that future milestone
payments will be paid, whether the product development efforts will
succeed, or whether other developed products will receive required
regulatory clearance or that, even if such regulatory clearance were
received, such products would ultimately achieve commercial success. Copies
of Medarex's public disclosure filings are available from its investor
relations department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Nichol Harber, Corporate
Communications (media), +1-609-430-2880, x2214, or Jean Mantuano,
Corporate Communications (media), +1-609-430-2880, x2221
|
